Edition:
United Kingdom

Concert Pharmaceuticals Inc (CNCE.OQ)

CNCE.OQ on NASDAQ Stock Exchange Global Market

18.85USD
9:00pm BST
Change (% chg)

$-0.31 (-1.62%)
Prev Close
$19.16
Open
$19.19
Day's High
$19.40
Day's Low
$18.63
Volume
48,133
Avg. Vol
144,179
52-wk High
$30.70
52-wk Low
$11.89

Latest Key Developments (Source: Significant Developments)

Concert Pharmaceuticals Inc Files For Mixed Shelf Offering Of Up To $250.0 Million - SEC Filing
Thursday, 1 Mar 2018 

March 1 (Reuters) - Concert Pharmaceuticals Inc ::CONCERT PHARMACEUTICALS INC FILES FOR MIXED SHELF OFFERING OF UP TO $250.0 MILLION - SEC FILING.  Full Article

Concert Pharmaceuticals Reports Qtrly Loss Per Share $0.26
Thursday, 1 Mar 2018 

March 1 (Reuters) - Concert Pharmaceuticals Inc ::CONCERT PHARMACEUTICALS REPORTS YEAR ENDED 2017 FINANCIAL RESULTS.CONCERT PHARMACEUTICALS INC - CTP-543 ON TRACK TO REPORT TOPLINE PHASE 2A RESULTS IN ALOPECIA AREATA BY YEAR-END.CONCERT PHARMACEUTICALS INC - NEW NEUROPSYCHIATRIC PRODUCT CANDIDATE POISED TO ENTER CLINICAL DEVELOPMENT IN 2018.CONCERT PHARMACEUTICALS INC - QTRLY LOSS PER SHARE $0.26.CONCERT PHARMACEUTICALS INC - EXPECTS TO REPORT TOPLINE DATA FROM 4 MG AND 8 MG COHORTS OF CTP-543 PHASE 2A TRIAL IN Q4 OF 2018.CONCERT PHARMACEUTICALS - CASH, CASH EQUIVALENTS AND INVESTMENTS AS OF DEC 31, 2017, TOTALED $203.2 MILLION VERSUS $96.2 MILLION AS OF DECEMBER 31, 2016.CONCERT PHARMACEUTICALS INC - EXPECTS ITS CASH, CASH EQUIVALENTS AND INVESTMENTS AS OF DECEMBER 31, 2017 TO BE SUFFICIENT TO FUND COMPANY INTO 2021.  Full Article

Concert Pharmaceuticals Initiates Enrollment In Second Cohort Of CTP-543 Trial
Monday, 12 Feb 2018 

Feb 12 (Reuters) - Concert Pharmaceuticals Inc ::CONCERT PHARMACEUTICALS ANNOUNCES INITIATION OF ENROLLMENT IN SECOND COHORT OF CTP-543 PHASE 2A TRIAL FOR ALOPECIA AREATA.CONCERT PHARMACEUTICALS INC - PHASE 2A TRIAL ON TRACK TO COMPLETE IN SECOND HALF OF 2018.  Full Article

Concert Pharma Says FDA Granted Fast Track Designation To CTP-543
Friday, 12 Jan 2018 

Jan 12 (Reuters) - Concert Pharmaceuticals Inc ::FDA GRANTS FAST TRACK DESIGNATION TO CONCERT PHARMACEUTICALS’ CTP-543 FOR THE TREATMENT OF ALOPECIA AREATA.CONCERT PHARMA SAYS U.S. FDA GRANTED FAST TRACK DESIGNATION FOR CO'S CTP-543.  Full Article

Concert Pharmaceuticals Announces Appointment Of Marc Becker As CFO
Monday, 18 Dec 2017 

Dec 18 (Reuters) - Concert Pharmaceuticals Inc ::CONCERT PHARMACEUTICALS ANNOUNCES THE APPOINTMENT OF MARC BECKER AS CHIEF FINANCIAL OFFICER.CONCERT PHARMACEUTICALS INC - ANNOUNCED APPOINTMENT OF MARC BECKER AS CHIEF FINANCIAL OFFICER, EFFECTIVE JANUARY 4, 2018.  Full Article

Concert Pharmaceuticals reports Q3 earnings per share $5.61
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Concert Pharmaceuticals Inc :Concert Pharmaceuticals reports third quarter 2017 financial results and provides company update.Q3 earnings per share $5.61.Q3 revenue $143.8 million.Q3 revenue view $11,700 -- Thomson Reuters I/B/E/S.Q3 earnings per share view $-0.54 -- Thomson Reuters I/B/E/S.Concert Pharmaceuticals Inc - ‍Expects cash, cash equivalents and investments as of September 30, 2017 to be sufficient to fund company into 2021​.  Full Article

Concert Pharmaceuticals announces completion of enrollment in First Cohort of CTP-543 phase 2a trial
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Concert Pharmaceuticals Inc :Concert Pharmaceuticals Inc announces completion of enrollment in First Cohort of CTP-543 phase 2a trial.Concert Pharmaceuticals Inc - ‍phase 2a trial on track to complete in second half of 2018​.  Full Article

Concert Pharma Says PTAB denies Incyte petition challenging CTP-543 patent
Thursday, 19 Oct 2017 

Oct 19 (Reuters) - Concert Pharmaceuticals Inc ::Concert Pharma says patent trials and appeal board of u.s. patent and trademark office has denied Incyte's petition to institute IPR​.  Full Article

Concert Pharma pays total of $30.8 mln to Hercules Capital
Friday, 8 Sep 2017 

Sept 8 (Reuters) - Concert Pharmaceuticals Inc ::Concert Pharmaceuticals- ‍on Sept 7, paid total of $30.8 million to hercules capital outstanding under loan and security agreement with Hercules dated June 8.Concert Pharmaceuticals-upon payment of $30.8 million outstanding indebtedness, obligations of co owed to hercules were paid in full​.  Full Article

Concert Pharmaceuticals reports Q2 loss per share $0.58
Tuesday, 8 Aug 2017 

Aug 8 (Reuters) - Concert Pharmaceuticals Inc :Concert Pharmaceuticals reports second quarter 2017 financial results and provides company update.Q2 loss per share $0.58.Q2 earnings per share view $-0.66 -- Thomson Reuters I/B/E/S.Concert Pharmaceuticals Inc - ‍company believes pro forma cash will be sufficient to fund company into 2021​.  Full Article

BRIEF-Concert Pharmaceuticals Inc Files For Mixed Shelf Offering Of Up To $250.0 Million - SEC Filing

* CONCERT PHARMACEUTICALS INC FILES FOR MIXED SHELF OFFERING OF UP TO $250.0 MILLION - SEC FILING Source text (http://bit.ly/2t6Qumw) Further company coverage: (Reuters.Brief@thomsonreuters.com)